TRIAL 2019
Ascolta
| Title | Malnutrition In Non-Celiac Wheat Sensitivity Patients |
| NCT Number | NCT02421796 |
| Conditions | Non-Celiac Wheat Sensitivity |
| Interventions | |
| Sponsor/Collaborators | University of Palermo |
| Gender | All |
| Age | 18 Years to 65 Years (Adult, Older Adult) |
| Phases | |
| Enrollment | 270 |
| Study Type | Observational |
| Study Designs | Observational Model: Case-Control|Time Perspective: Prospective |
| Start Date | 01/05/2015 |
| Completion Date | 01/06/2019 |
| Locations | Antonio Carroccio, Sciacca, Agrigento, Italy|Pasquale Mansueto, Palermo, Italy |
| URL | https://ClinicalTrials.gov/show/NCT02421796 |
| Title | Osteoporosis In Non-Celiac Wheat Sensitivity Patients |
| NCT Number | NCT02421783 |
| Conditions | Non-celiac Wheat Sensitivity |
| Interventions | |
| Sponsor/Collaborators | University of Palermo |
| Gender | All |
| Age | 18 Years to 65 Years (Adult, Older Adult) |
| Phases | |
| Enrollment | 270 |
| Study Type | Observational |
| Study Designs | Observational Model: Case-Control|Time Perspective: Prospective |
| Start Date | 01/05/2015 |
| Completion Date | 01/06/2019 |
| Locations | Antonio Carroccio, Sciacca, Agrigento, Italy|Pasquale Mansueto, Palermo, Italy |
| URL | https://ClinicalTrials.gov/show/NCT02421783 |
| Title | Malnutrition In Non-Celiac Wheat Sensitivity Patients |
| NCT Number | NCT02421796 |
| Conditions | Non-Celiac Wheat Sensitivity |
| Interventions | |
| Sponsor/Collaborators | University of Palermo |
| Gender | All |
| Age | 18 Years to 65 Years (Adult, Older Adult) |
| Phases | |
| Enrollment | 270 |
| Study Type | Observational |
| Study Designs | Observational Model: Case-Control|Time Perspective: Prospective |
| Start Date | 01/05/2015 |
| Completion Date | 01/06/2019 |
| Locations | Antonio Carroccio, Sciacca, Agrigento, Italy|Pasquale Mansueto, Palermo, Italy |
| URL | https://ClinicalTrials.gov/show/NCT02421796 |
| Title | Osteoporosis In Non-Celiac Wheat Sensitivity Patients |
| NCT Number | NCT02421783 |
| Conditions | Non-celiac Wheat Sensitivity |
| Interventions | |
| Sponsor/Collaborators | University of Palermo |
| Gender | All |
| Age | 18 Years to 65 Years (Adult, Older Adult) |
| Phases | |
| Enrollment | 270 |
| Study Type | Observational |
| Study Designs | Observational Model: Case-Control|Time Perspective: Prospective |
| Start Date | 01/05/2015 |
| Completion Date | 01/06/2019 |
| Locations | Antonio Carroccio, Sciacca, Agrigento, Italy|Pasquale Mansueto, Palermo, Italy |
| URL | https://ClinicalTrials.gov/show/NCT02421783 |
Trial autorizzati dal Comitato Etico nell'anno 2017
|
Titolo dello studio |
Tipologia dello studio (farmaci/ dispositivi medici/ non interventistico/ osservazionale) |
Responsabile Scientifico |
fase (I/II/III/IV) |
trial multinazionali o di network (sì/no) |
| DA VINCI STUDY – EU-WIDE CROSS-SECTIONAL OBSERVATIONAL STUDY OF LIPID-MODIFYING THERAPY USE IN SECONDARY AND PRIMARY CARE DA VINCI | Osservazionale | Prof. M. Averna | Multinazionale | |
| COMPRENDERE L’ESPERIENZA DEI PAZIENTI INTOLLERANTI ALLE STATINE: SVILUPPO E VALUTAZIONE PRELIMINARE DI UN QUESTIONARIO AUTOCOMPILATO DAL PAZIENTE – PROTOCOLLO AMGEN N.20160434 – V. 9 –HRA N. 2276 – 2199 | Prof. M. Averna | |||
| STUDIO AMGEN 20130296 - “OBSERVATIONAL SERIAL CHART REVIEW OF REPATHA® USE IN EUROPEAN SUBJECTS WITH HYPERLIPIDAEMIA” | Osservazionale | Prof. M. Averna | Multinazionale | |
| PROSISA – PROJECT STATIN INTOLERANCE SISA | Osservazionale | Prof. M. Averna | Multicentrico, nazionale promosso dalla SISA | |
| SCREENING PROTOCOL FOR A GENE THERAPY TRIAL IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) (FHGT001) | Prof. M. Averna | |||
| AAV8-MEDIATED LOW DENSITY LIPOPROTEIN RECEPTOR GENE REPLACEMENT IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (FHGT002) | Prof. M. Averna | |||
| OBSERVATIONAL RETROSPECTIVE STUDY ON LIPID ABNORMALITIES IN PATIENTS ON STATIN THERAPY (TREAT) PROMOSSO DA FONDAZIONE S.I.S.A. | Prof. M. Averna | |||
| STUDIO OSSERVAZIONALE MULTINAZIONALE TESO A VALUTARE LA SICUREZZA DI REPATHA IN GRAVIDANZA® (20150162) | Prof. M. Averna | |||
| STUDIO MULTICENTRICO, IN APERTO, A SINGOLO BRACCIO, VOLTO A CARATTERIZZARE L’EFFICACIA, LA SICUREZZA E LA TOLLERABILITA’ DI EVOLOCUMAB PER LA RIDUZIONE DEL COLESTEROLO LEGATO ALLE LIPOPROTEINE A BASSA DENSITA’ (C-LDL) IN AGGIUNTA ALLA DIETA E ALLA TERAPIA IPOLIPEMIZZANTE IN SOGGETTI PEDIATRICI DAI 10 AI 17 ANNI DI ETA’ AFFETTI DA IPERCOLESTEROLEMIA FAMILIARE ETEROZIGOTE (HEFH) O IPERCOLESTEROLEMIA FAMILIARE OMOZIGOTE (HOFH) (AMGEN 20120124) | Prof. M. Averna | |||
| STUDIO MULTICENTRICO, RANDOMIZZATO, IN DOPPIO CIECO, A GRUPPI PARALLELI, CONTROLLATO VERSO PLACEBO VOLTO A CARATTERIZZARE L’EFFICACIA, LA SICUREZZA E LA TOLLERABILITA’ DI 24 SETTIMANE DI TRATTAMENTO CON EVOLOCUMAB PER LA RIDUZIONE DEL COLESTEROLO LEGATO ALLE LIPOPROTEINE A BASSA DENSITA’ (C-LDL) IN AGGIUNTA ALLA DIETA E ALLA TERAPIA IPOLIPEMIZZANTE IN SOGGETTI PEDIATRICI DAI 10 AI 17 ANNI DI ETA’ AFFETTI DA IPERCOLESTEROLEMIA FAMILIARE ETEROZIGOTE (HEFH) (AMGEN 20120123) | Prof. M. Averna | |||
| STUDIO MULTICENTRICO DI FASE III, RANDOMIZZATO, IN DOPPIO CIECO, CONTROLLATO VERSO PLACEBO PER VALUTARE L’EFFICACIA E LA SICUREZZA DI ELAFIBRANOR IN PAZIENTI CON STEATOEPATITE NON ALCOLICA (NASH) E FIBROSI (GFT505-315-1) (2016) (STUDIO RESOLVE-IT) | Prof. M. Averna | III | ||
| STUDIO DI ESTENSIONE IN APERTO DI VOLANESORSEN SOMMINISTRATO PER VIA SOTTOCUTANEA A PAZIENTI AFFETTI DA SINDROME CHILOMICRONEMICA FAMILIARE (FAMILIAL CHYLOMICRONEMIA SYNDROME, FCS) (IONIS 304801-CS7) | Prof. M. Averna | |||
| LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER) (AEGR-733-025) | Prof. M. Averna | |||
| STUDIO INTERNAZIONALE, MULTICENTRICO, A BRACCIO SINGOLO, IN APERTO PER DOCUMENTARE SICUREZZA, TOLLERABILITA’ ED EFFETTO DI ALIROCUMAB SULLE LIPOPROTEINE ATEROGENE IN PAZIENTI AD ALTO RISCHIO CARDIOVASCOLARE CON IPERCOLESTEROLEMIA SEVERA NON ADEGUATAMENTE CONTROLLATA CON TERAPIE IPOLIPEMIZZANTI COMUNEMENTE UTILIZZATE (LPS14245) | Prof. M. Averna | |||
| RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF ISIS 304801 ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) | Prof. M. Averna | III | ||
| PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS (B1481022) | Prof. M. Averna | III | ||
| PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS (B1481038) | Prof. M. Averna | III | ||
| LPLD REGISTRY, OBSERVATIONAL LONGITUDINAL PHARMACO-EPIDEMIOLOGIC STUDY IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) PATIENTS, EITHER TREATED OR NOT TREATED WITH ALIPOGENE TIPARVOVEC (GLYBERA®) | Prof. M. Averna | |||
| OPEN-LABEL EXTENSION STUDY OF EFC12492, R727-CL-1112, EFC12732, & LTS11717 STUDIES TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF ALIROCUMAB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (LTS13463) | Prof. M. Averna | |||
| RANDOMISED CONTROLLED TRIAL OF LIFESTYLE VERSUS EZETIMIBE PLUS LIFESTYLE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS | Prof. M. Averna | |||
| Studio di outcome cardiovascolare, trial di indagine sulla sicurezza cardiovascolare della semaglutide in pazienti con diabete tipo 2 (PIONEER 6). Trial ID NN9924-4221 - codice EudraCT 2015-003563-10 | clinico su farmaci | Prof. S. Buscemi | III | |
| Studio su efficacia e sicurezza di liraglutide 3.0 mg in soggetti con sovrappeso o obesità e diabete mellito tipo 2 trattato con insulin basale (SCALEInsulin). Trial ID NN8022-4272 - codice EudraCT 2015-005619-33 |
clinico su farmaci | Prof. S. Buscemi | III | Centro coordinatore nazionale |
| CAIN457A3302-OPTIMISE STUDY: Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 week study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg s.c. | clinico su farmaci | Prof.ssa M.R. Bongiorno | ||
| Studio epidemiologico per la validazione di un questionario sulla qualità di vita in pazienti affetti da idrosadenite suppurativa (HS)(HIDRAdisk: validation of a new Quality Of Life questionnaire in Hidradenitis Suppurativa patients. | Prof.ssa M.R. Bongiorno | |||
| CAIN457A3403-SERENA:Secukinumab real-life use in Pso, PsA and AS. Long-term observational, prospective study to collect in a real life setting data on the retention, effectiveness, safety, treatment pattern, quality of life, and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis, psoriatic arthritis or ankylosing spondylitis. | Osservazionale | Prof.ssa M.R. Bongiorno | ||
| CAIN457AIT02-TRANSITION: Studio osservazionale, cross-sectional per valutare la percentuale di pazienti, affetti da psoriasi cronica a placche da moderata a severa, aventi una rispostaparziale e subottimale al trattamento con ciclosporina. | Osservazionale | Prof.ssa M.R. Bongiorno |
